

# Does Aneurysmal Wall Enhancement on Vessel Wall MRI Help to Distinguish Stable From Unstable Intracranial Aneurysms?

Myriam Edjlali, MD; Jean-Christophe Gentric, MD; Christine Régent-Rodriguez, MD; Denis Trystram, MD; Wajih Ben Hassen, MD; Stéphanie Lion; François Nataf, MD; Jean Raymond, MD; Oliver Wieben, PhD; Patrick Turski, MD; Jean-Francois Meder, PhD; Catherine Oppenheim, PhD; Olivier Naggara, PhD

**Background and Purpose**—Arterial wall enhancement on vessel wall MRI was described in intracranial inflammatory arterial disease. We hypothesized that circumferential aneurysmal wall enhancement (CAWE) could be an indirect marker of aneurysmal wall inflammation and, therefore, would be more frequent in unstable (ruptured, symptomatic, or undergoing morphological modification) than in stable (incidental and nonevolving) intracranial aneurysms.

**Methods**—We prospectively performed vessel wall MRI in patients with stable or unstable intracranial aneurysms. Two readers independently had to determine whether a CAWE was present.

**Results**—We included 87 patients harboring 108 aneurysms. Interreader and intrareader agreement for CAWE was excellent ( $\kappa=0.85$ ; 95% confidence interval, 0.75–0.95 and  $\kappa=0.90$ ; 95% confidence interval, 0.83–0.98, respectively). A CAWE was significantly more frequently seen in unstable than in stable aneurysms (27/31, 87% versus 22/77, 28.5%, respectively;  $P<0.0001$ ). Multivariate logistic regression, including CAWE, size, location, multiplicity of aneurysms, and daily aspirin intake, revealed that CAWE was the only independent factor associated with unstable status (odds ratio, 9.20; 95% confidence interval, 2.92–29.0;  $P=0.0002$ ).

**Conclusions**—CAWE was more frequently observed in unstable intracranial aneurysms and may be used as a surrogate of inflammatory activity in the aneurysmal wall. (*Stroke*. 2014;45:3704-3706.)

**Key Words:** aneurysm ■ inflammation ■ magnetic resonance imaging

Unruptured intracranial aneurysms occur in 4% of adults, usually remaining silent unless rupture occurs.<sup>1</sup> Determining individual criteria for predicting instability is important for therapeutic decision making.<sup>2–4</sup> Histopathologic evidence from human and animal studies has lent support to the concept that inflammation plays a major role in aneurysm formation, growth, and rupture.<sup>5</sup> To target in vivo inflammation of the aneurysm wall, some authors proposed ultrasmall superparamagnetic particles of iron oxide (ferumoxytol) as a contrast agent for MRI. They demonstrated that circumferential uptake in aneurysm walls obtained 24 to 72 hours after infusion was highly predictive of rupture within 6 months.<sup>6</sup> Using 3T gadolinium-enhanced vessel wall MRI (VW-MRI), a preliminary report also described circumferential aneurysmal wall enhancement (CAWE) on 5 ruptured aneurysms.<sup>7</sup> We hypothesized that CAWE could be an indirect marker of inflammation and would be more frequent in unstable (ruptured, symptomatic, or undergoing morphological modification) than in stable (incidental and nonevolving) aneurysms.

## Materials and Methods

### Patients

After institutional review board approval, we prospectively included, between November 2012 and March 2014, patients with intradural saccular aneurysm.

Patients and aneurysm (status, size, and location) characteristics were recorded. An aneurysm was considered to be evolving at the time of VW-MRI in case of morphological change on the previous MR angiography, or nonevolving, otherwise. Aneurysm status was categorized as unstable (recently [within 24 hours] ruptured, symptomatic, or evolving) or as stable (fortuitous presentation, nonevolving on serial MR angiography).

### Imaging Protocol

VW-MRI was acquired on a 3T MR scanner (MR 750; GE Healthcare, Milwaukee, WI) with a 16-channel head coil. The protocol included a 3D T1 FSE sequence (field of view, 23×23×16 cm<sup>3</sup>; repetition time/echo time, 600/11.5 ms; matrix, 288×288×160 interpolated to 512×512×320; spatial resolution: 0.45×0.45×0.5 mm)<sup>8</sup> pre- and post-gadolinium (10 mL of gadoteric acid; Dotarem, Guerbet, France). The total scan time was 4 minutes 16 s per sequence.

Received July 1, 2014; final revision received September 9, 2014; accepted September 15, 2014.

From the Departments of Radiology (M.E., C.R.-R., D.T., W.B.H., S.L., J.F.M., C.O., O.N.) and Neurosurgery (F.N.), Université Paris Descartes Sorbonne Paris Cité, INSERM S894, Centre Hospitalier Sainte-Anne, Paris, France; Department of Interventional Neuroradiology, University of Montreal, CHUM Notre-Dame Hospital, Montreal, Quebec, Canada (J.-C.G., J.R.); and the Departments of Medical Physics and Radiology (O.W., P.T.), University of Wisconsin, Madison.

Correspondence to Myriam Edjlali, MD, CH Sainte-Anne, 1 Rue Cabanis, 75014 Paris, France. E-mail m.edjlali@ch-sainte-anne.fr

© 2014 American Heart Association, Inc.

*Stroke* is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.114.006626

**Image Analysis**

Two readers (4 and 5 years of experience in vascular neuroimaging), from 2 different institutions, blinded to the clinical data but aware of patients aneurysm location(s), independently reviewed the images. One reader performed a second reading session 6 months later. Multiplanar oblique reconstructions obtained from precontrast and postcontrast-enhanced 3-dimensional VW-MRI were analyzed after coregistration. Readers had to determine whether a CAWE, defined as a circumferential, unequivocal enhancement on postgadolinium VW-MRI, was present or not. Discordances were resolved by a third reader (10 years of experience in vascular neuroimaging).


**Statistical Analysis**

Inter- and intrareader agreement for CAWE presence was assessed using  $\kappa$  statistics with their 95% confidence intervals. Statistical analysis was performed using MedCalc software to establish associations between unstable status and daily aspirin intake, aneurysm characteristics (size considered as a continuous variable, anterior versus posterior location, multiples), tobacco use, diabetes mellitus, and CAWE. Significance of intergroup differences was assessed using Fisher exact test for categorical variables and Mann–Whitney *U* test for continuous variables. Multivariate logistic regression analysis was performed to determine factors independently associated with unstable status using variables that reached  $P < 0.2$  on univariate analysis. A 2-sided  $P$  value  $< 0.05$  was considered significant.

**Results**

Among 89 included patients (110 aneurysms), 2 patients were excluded (movement artifacts). The final population included 87 patients (57±21 years), with 108 aneurysms (31 unstable; mean size [range], 6 [4–8] mm; 96 in anterior circulation).

Interreader and intrareader agreement for CAWE presence were excellent ( $\kappa = 0.85$ ; 95% confidence interval, 0.75–0.95 and  $\kappa = 0.90$ ; 95% confidence interval, 0.83–0.98, respectively). A CAWE was more frequently seen in unstable than in stable aneurysms (27/31, 87% versus 22/77, 28.5%, respectively;  $P < 0.0001$ ; Figures 1 and 2). A CAWE was observed in 16 of 17 ruptured aneurysms, 5 of 5 demonstrating change



**Figure 2.** Vessel wall MRI in aneurysms presenting circumferential arterial wall enhancement (CAWE): symptomatic (thunderclap headache, **A** and **B**) and modified in size between 2 follow-up MRI (**C** and **D**) aneurysms.

in morphology, and 6 of 9 symptomatic aneurysms. There was no link between CAWE and aneurysm size. Multivariate logistic regression analysis (Table) revealed that CAWE was the only independent factor associated with unstable status (odds ratio, 9.20; 95% confidence interval, 2.92–29.0;  $P = 0.0002$ ).

**Discussion**


Our study showed that circumferential aneurysmal wall enhancement is more frequently observed in unstable than in stable aneurysms.

Although aneurysmal wall inflammation is hypothesized to contribute to progression toward rupture,<sup>5</sup> there is currently no noninvasive means to detect inflammation in intracranial aneurysms routinely. Although the use of MR specific target of inflammation, such as ultrasmall particles of iron oxide, is difficult to implement in routine clinical practice, CAWE is reproducible and assessable by the naked eye without post processing.

**Table. Multivariate Logistic Regression Analysis for Factors Associated With Unstable Aneurysmal Status**

	Univariate P Value	Multivariate P Value	OR (95% CI)
Multiple aneurysms	0.08	0.62	0.74 (0.22–2.48)
Circumferential arterial wall enhancement	<0.0001	0.0002	9.20 (2.92–29.01)
Aneurysm size, mm	0.44	*	*
Daily aspirin intake	0.03	0.49	2.09 (0.26–16.93)
Anterior aneurysm location	0.30	*	*
Tobacco use	0.25	*	*
Diabetes	0.74	*	*

\*Not included in the model.



**Figure 1.** Vessel wall MRI in a stable aneurysm (**A** and **B**) with no circumferential arterial wall enhancement (CAWE) and in a ruptured aneurysm (**C** and **D**) with CAWE.

Different observations support that arterial wall enhancement can be used as an indirect marker of vessel wall inflammation, and therefore as a potential marker of aneurysm instability. First, mural artery contrast uptake was described in intracranial vessel wall inflammation, eg, in active cerebral inflammatory vasculitis,<sup>9,10</sup> and is thought to be linked to vasa vasorum density. This is of major interest, because increase of density of vasa vasorum was also associated with morphological modification and rupture risk of intracranial aneurysms.<sup>9</sup> Second, a recent case series of 5 patients highlighted the potential use of CAWE to identify ruptured aneurysms in patients presenting with subarachnoid hemorrhage and multiple aneurysms.<sup>7</sup> All but 1 of our 17 ruptured aneurysms demonstrated CAWE. Histopathologic studies showed that, although less frequent than thickened wall with inflammatory process, ruptured aneurysm wall could also present as extremely thin thrombosis-lined hypocellular wall.<sup>11</sup> This feature may explain why the aneurysmal wall of 1 ruptured aneurysm did not enhance. Noteworthy, we demonstrated that CAWE was also present not only in the majority of symptomatic aneurysms or aneurysms with change in morphology but also in almost one third of presumably stable aneurysms. Histopathologic findings support that inflammatory cell infiltration is an ongoing process along different stages of an aneurysm life cycle.<sup>5</sup> Gadolinium-enhanced VW-MRI may, therefore, have a potential use to monitor the aneurysm wall inflammatory process.

One of the limitations of our study is a referral bias because it was performed in a tertiary center in which a high proportion of patients were referred for ruptured or symptomatic aneurysms, leading to a higher proportion (31/108) of unstable aneurysms compared with what would be expected in other centers. Because the diagnostic value of CAWE to distinguish stable versus unstable aneurysms may depend on the prevalence of the latter, we did not estimate its specificity or sensitivity. Extrapolation of findings from our population to another may be, therefore, unwarranted. Larger cohorts are needed to prospectively follow presumably stable aneurysms to confirm the clinical use of CAWE to predict instability, before the implementation of VW-MRI into routine clinical practice.

In conclusion, circumferential arterial wall enhancement helps in distinguishing stable from symptomatic, modified,

or ruptured intracranial aneurysms. Longitudinal prospective cohort studies are needed to confirm that 3T gadolinium-enhanced VW-MRI is a useful tool for the noninvasive follow-up of unruptured aneurysms.

### Sources of Funding

This work was supported, in part, by the Société Française Neuro-vasculaire.

### Disclosures

None.

### References

1. Wiebers DO, Whisnant JP, Huston J III, Meissner I, Brown RD Jr, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. *Lancet*. 2003;362:103–110.
2. Naggara ON, Lecler A, Oppenheim C, Meder JF, Raymond J. Endovascular treatment of intracranial unruptured aneurysms: a systematic review of the literature on safety with emphasis on subgroup analyses. *Radiology*. 2012;263:828–835.
3. Greving JP, Wermer MJ, Brown RD Jr, Morita A, Juvela S, Yonekura M, et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. *Lancet Neurol*. 2014;13:59–66.
4. Naggara O, Darsaut T, Trystram D, Tselikas L, Raymond J. Unruptured intracranial aneurysms: why we must not perpetuate the impasse for another 25 years. *Lancet Neurol*. 2014;13:537–538.
5. Chalouhi N, Hoh BL, Hasan D. Review of cerebral aneurysm formation, growth, and rupture. *Stroke*. 2013;44:3613–3622.
6. Hasan D, Chalouhi N, Jabbour P, Dumont AS, Kung DK, Magnotta VA, et al. Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. *Stroke*. 2012;43:3258–3265.
7. Matouk CC, Mandell DM, Günel M, Bulsara KR, Malhotra A, Hebert R, et al. Vessel wall magnetic resonance imaging identifies the site of rupture in patients with multiple intracranial aneurysms: proof of principle. *Neurosurgery*. 2013;72:492–496, discussion 496.
8. Edjlali M, Roca P, Rabrait C, Naggara O, Oppenheim C. 3D fast spin-echo T1 black-blood imaging for the diagnosis of cervical artery dissection. *AJNR Am J Neuroradiol*. 2013;34:E103–E106.
9. Portanova A, Hakakian N, Mikulis DJ, Virmani R, Abdalla WM, Wasserman BA. Intracranial vasa vasorum: insights and implications for imaging. *Radiology*. 2013;267:667–679.
10. Swartz RH, Bhuta SS, Farb RI, Agid R, Willinsky RA, Terbrugge KG, et al. Intracranial arterial wall imaging using high-resolution 3-tesla contrast-enhanced MRI. *Neurology*. 2009;72:627–634.
11. Chyatte D, Bruno G, Desai S, Todor DR. Inflammation and intracranial aneurysms. *Neurosurgery*. 1999;45:1137–1146.

## Does Aneurysmal Wall Enhancement on Vessel Wall MRI Help to Distinguish Stable From Unstable Intracranial Aneurysms?

Myriam Edjlali, Jean-Christophe Gentric, Christine Régent-Rodriguez, Denis Trystram, Wajih Ben Hassen, Stéphanie Lion, François Nataf, Jean Raymond, Oliver Wieben, Patrick Turski, Jean-Francois Meder, Catherine Oppenheim and Olivier Naggara

*Stroke*. 2014;45:3704-3706; originally published online October 16, 2014;

doi: 10.1161/STROKEAHA.114.006626

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2014 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/content/45/12/3704>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Stroke* is online at:  
<http://stroke.ahajournals.org/subscriptions/>